Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Qiagen ( (QGEN) ) has provided an announcement.
QIAGEN has disclosed a managerial transaction involving Chief Financial Officer and managing board member Roland Sackers, following the implementation of a synthetic share repurchase program. Under a share consolidation approved by shareholders in 2025, every 20 issued QIAGEN shares were merged into 19, resulting in Sackers’ holdings being reduced by 18,383 shares to 349,195 common shares, part of which are pledged under a securities lending arrangement; the transaction, executed outside a trading venue on January 7, 2026, reflects the technical adjustment of insider holdings following the capital measure and may be watched by investors as an indicator of governance transparency and capital-structure management.
The most recent analyst rating on (QGEN) stock is a Hold with a $48.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
QIAGEN N.V. is a life sciences and molecular diagnostics company based in Venlo, Netherlands, with its shares listed on multiple European exchanges as well as the NYSE and Swiss markets. The company operates globally, providing sample and assay technologies for molecular diagnostics, applied testing, pharmaceutical research and academic research, and is a widely followed stock in both European and U.S. capital markets.
Average Trading Volume: 1,155,025
Technical Sentiment Signal: Strong Buy
Current Market Cap: $9.99B
See more data about QGEN stock on TipRanks’ Stock Analysis page.